The effect of N-acetylcysteine treatment to prevent the progression of multiple organ failure N-asetil sistein tedavisinin çoklu organ yetmezliǧi gelişmesini önlemedeki yeri


AKINCI S. B., Erden I. A., Kanbak M., AYPAR Ü.

Turk Anesteziyoloji ve Reanimasyon Dernegi Dergisi, cilt.33, sa.1, ss.76-81, 2005 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 1
  • Basım Tarihi: 2005
  • Dergi Adı: Turk Anesteziyoloji ve Reanimasyon Dernegi Dergisi
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.76-81
  • Anahtar Kelimeler: Antioxidants, Intensive care, Multiple organ failure, N-acetylcysteine
  • Lokman Hekim Üniversitesi Adresli: Evet

Özet

Aim: We investigated whether prolonged infusion of the oxygen free radical scavenger N-acetylcysteine (NAC) started immediately after admission to intensive care unit (ICU) could ameliorate the development or progression of multiple organ failure (MOF). Materials and Methods: After receiving local ethics committee approval, 26 patients enrolled into a prospective, randomized, double-blinded, placebo-controlled trial. Patients were allocated to recieve either NAC in 5 % dextrose 40 mg/kg/day in four divided doses or the same volume of. 5 % dextrose. Two patients were withdrawn because of ICU stay<24 hrs. Organ function was assessed by the Sequential Organ Failure Assessment (SOFA) scores on admission and then daily. Chi-square, Mann Whitney U tests were used for statistical analysis. Results: In the NAC treatment group, the maximum SOFA coagulation score was higher than the control group (P<0.05). There were no significant differences between groups in the remaining SOFA organ dysfunction paremeters, maximum or change in SOFA score, length of intensive care stay, days of mechanical ventilation or mortality. Conclusion: NAC (40 mg/kg/day) started immediately after admission to the ICU did not ameliorate the progression of MOF in this small cohort of patients. While a larger trial is needed to definitively answer this question we believe routine prophylactic use of low-dose NAC to protect against MOF in all critically ill patients cannot be recomended at this time.